Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

TransMedics (TMDX) Accumulated Depreciation & Amortization (2018 - 2025)

TransMedics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $66.1 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $66.1 million for Q4 2025, up 62.27% from a year ago — trailing twelve months through Dec 2025 was $66.1 million (up 62.27% YoY), and the annual figure for FY2025 was $66.1 million, up 62.27%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $66.1 million at TransMedics, up from $60.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for TMDX hit a ceiling of $66.1 million in Q4 2025 and a floor of $9.7 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $32.6 million (2024), compared with a mean of $35.1 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 21.28% in 2021 and later skyrocketed 99.59% in 2024.
  • TransMedics' Accumulated Depreciation & Amortization stood at $9.7 million in 2021, then surged by 34.86% to $13.1 million in 2022, then soared by 62.18% to $21.3 million in 2023, then skyrocketed by 91.21% to $40.7 million in 2024, then surged by 62.27% to $66.1 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $66.1 million (Q4 2025), $60.6 million (Q3 2025), and $53.8 million (Q2 2025) per Business Quant data.